How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

129,191 results for

Demulen 1/35

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Isolation and characterization of Burkholderia fungorum Gan-35 with the outstanding ammonia nitrogen-degrading ability from the tailings of rare-earth-element mines in southern Jiangxi, China (PubMed)

. In this study, a bacterium with the outstanding ammonia nitrogen-degrading capability was isolated from the tailings of REE mines in southern Jiangxi Province, China. This strain was identified as Burkholderia fungorum Gan-35 according to phenotypic and phylogenetic analyses. The optimal conditions for ammonia-nitrogen degradation by strain Gan-35 were determined as follows: pH value, 7.5; inoculum dose, 10%; incubation time, 44 h; temperature, 30 °C; and C/N ratio, 15:1. Strain Gan-35 degraded 68.6 (...) Isolation and characterization of Burkholderia fungorum Gan-35 with the outstanding ammonia nitrogen-degrading ability from the tailings of rare-earth-element mines in southern Jiangxi, China The exploitation of rare-earth-element (REE) mines has resulted in severe ammonia nitrogen pollution and induced hazards to environments and human health. Screening microorganisms with the ammonia nitrogen-degrading ability provides a basis for bioremediation of ammonia nitrogen-polluted environments

Full Text available with Trip Pro

2017 AMB Express

142. Vaccination Coverage Among Children Aged 19–35 Months — United States, 2016 (PubMed)

Vaccination Coverage Among Children Aged 19–35 Months — United States, 2016 Vaccination is the most effective intervention to reduce morbidity and mortality from vaccine-preventable diseases in young children (1). Data from the 2016 National Immunization Survey-Child (NIS-Child) were used to assess coverage with recommended vaccines (2) among children aged 19-35 months in the United States. Coverage remained ≥90% for ≥3 doses of poliovirus vaccine (91.9%), ≥1 dose of measles, mumps (...) , and rubella vaccine (MMR) (91.1%), ≥1 dose of varicella vaccine (90.6%), and ≥3 doses of hepatitis B vaccine (HepB) (90.5%). Coverage in 2016 was approximately 1-2 percentage points lower than in 2015 for ≥3 doses of diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP), ≥3 doses of poliovirus vaccine, the primary Haemophilus influenzae type b (Hib) series, ≥3 HepB doses, and ≥3 and ≥4 doses of pneumococcal conjugate vaccine (PCV), with no changes for other vaccines. More direct evaluation

Full Text available with Trip Pro

2017 MMWR. Morbidity and mortality weekly report

143. IL-6/IL-12 Cytokine Receptor Shuffling of Extra- and Intracellular Domains Reveals Canonical STAT Activation via Synthetic IL-35 and IL-39 Signaling (PubMed)

IL-6/IL-12 Cytokine Receptor Shuffling of Extra- and Intracellular Domains Reveals Canonical STAT Activation via Synthetic IL-35 and IL-39 Signaling IL-35 and IL-39 are recently discovered shared members of the IL-6- and IL-12-type cytokine family with immune-suppressive capacity. IL-35 has been reported to induce the formation of four different receptor complexes: gp130:IL-12β2, gp130:gp130, IL-12β2:IL-12β2, and IL-12β2:WSX-1. IL-39 was proposed to form a gp130:IL-23R receptor complex. IL-35 (...) , but not IL-39, has been reported to activate non-conventional STAT signaling, depending on the receptor complex and target cell. Analyses of IL-35 and IL-39 are, however, hampered by the lack of biologically active recombinant IL-35 and IL-39 proteins. Therefore, we engineered chimeric cytokine receptors to accomplish synthetic IL-35 and IL- 39 signaling by shuffling the extra- and intracellular domains of IL-6/IL-12-type cytokine receptors, resulting in biological activity for all previously described

Full Text available with Trip Pro

2017 Scientific reports

144. Roux-en-Y gastric bypass stands the test of time: 5-year results in low body mass index (30-35 kg/m(2)) Indian patients with type 2 diabetes mellitus. (PubMed)

prospective observational study was begun in January 2006. A total of 52 patients with uncontrolled T2DM and a body mass index of 30-35 kg/m(2) elected to undergo laparoscopic Roux-en-Y gastric bypass. The duration of T2DM was 3.5-14.5 years (median 8.4). Of the 52 patients, 61.5% had hypertension and 59.6% had dyslipidemia. Remission of T2DM and other components of the metabolic syndrome were assessed. All patients were followed up for 5 years.The median percentage of excess weight loss was 72.2% at 1 (...) Roux-en-Y gastric bypass stands the test of time: 5-year results in low body mass index (30-35 kg/m(2)) Indian patients with type 2 diabetes mellitus. Our objective was to evaluate the long-term results of laparoscopic Roux-en-Y gastric bypass on excess weight loss, remission of the metabolic syndrome, and complications in Indian patients with uncontrolled type 2 diabetes mellitus (T2DM) with a body mass index of 30-35 kg/m(2). The setting was a corporate hospital in Mumbai, India.The present

2017 Surgery for Obesity and Related Diseases

145. Visceral fat area as a new predictor of short-term diabetes remission after Roux-en-Y gastric bypass surgery in Chinese patients with a body mass index less than 35 kg/m2. (PubMed)

Visceral fat area as a new predictor of short-term diabetes remission after Roux-en-Y gastric bypass surgery in Chinese patients with a body mass index less than 35 kg/m2. Metabolic surgery has been proposed for inadequately controlled type 2 diabetes mellitus (T2DM) in association with obesity. However, prediction of successful T2DM remission after surgery has not been clearly studied in Chinese patients. The objective of this study was to predict the outcome in those with T2DM after metabolic (...) surgery to help in patient selection.A retrospective review of prospectively collected data of 68 ethnic Chinese with mean body mass index (BMI) of 31.5 and T2DM were examined for the metabolic outcomes at 1 year after Roux-en-Y gastric bypass (RYGB). Visceral and abdominal subcutaneous fat areas were assessed using magnetic resonance imaging before and 1 year after RYGB. Remission was defined as a glycated hemoglobin (HbA1 c)<6.5% and no medications at 1 year. Binary logistic regression analysis

2017 Surgery for Obesity and Related Diseases

146. Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017 (PubMed)

Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017 28483197 2018 03 09 1873-2518 35 24 2017 05 31 Vaccine Vaccine Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years (...) of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402]. 3279 S0264-410X(17)30582-0 10.1016/j.vaccine.2017.04.081 Iro Mildred A MA Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK. Electronic address: mildred.iro@paediatrics.ox.ac.uk. Snape Matthew D MD Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK. Voysey

Full Text available with Trip Pro

2017 Vaccine Controlled trial quality: uncertain

147. Corrigendum to "Effects of Triple P parenting intervention on child health outcomes for childhood asthma and eczema: Randomised controlled trial" [Behav. Res. Ther. 83 (2016) 35-44]. (PubMed)

, Australia. eng Journal Article Published Erratum 2017 01 24 England Behav Res Ther 0372477 0005-7967 Behav Res Ther. 2016 Aug;83:35-44 27295179 2017 1 29 6 0 2017 1 29 6 1 2017 1 29 6 0 ppublish 28129879 S0005-7967(16)30244-3 10.1016/j.brat.2016.12.017 (...) Corrigendum to "Effects of Triple P parenting intervention on child health outcomes for childhood asthma and eczema: Randomised controlled trial" [Behav. Res. Ther. 83 (2016) 35-44]. 28129879 2018 02 03 1873-622X 92 2017 05 Behaviour research and therapy Behav Res Ther Corrigendum to "Effects of Triple P parenting intervention on child health outcomes for childhood asthma and eczema: Randomised controlled trial" [Behav. Res. Ther. 83 (2016) 35-44]. 107 S0005-7967(16)30244-3 10.1016/j.brat

2017 Behaviour research and therapy Controlled trial quality: uncertain

148. Corrigendum to "A randomised, controlled, double-blind crossover study on the effects of isovolumetric and isoeffective infusions of colloid versus crystalloid on blood volume, cardiac output and renal blood flow" [Clin Nutr 35 (2016) S22]. (PubMed)

Corrigendum to "A randomised, controlled, double-blind crossover study on the effects of isovolumetric and isoeffective infusions of colloid versus crystalloid on blood volume, cardiac output and renal blood flow" [Clin Nutr 35 (2016) S22]. 27771021 2018 10 05 1532-1983 36 1 2017 02 Clinical nutrition (Edinburgh, Scotland) Clin Nutr Corrigendum to "A randomised, controlled, double-blind crossover study on the effects of isovolumetric and isoeffective infusions of colloid versus crystalloid (...) on blood volume, cardiac output and renal blood flow" [Clin Nutr 35 (2016) S22]. 319 S0261-5614(16)31273-0 10.1016/j.clnu.2016.10.001 Bragg D D Department of Gastrointestinal Surgery, University of Nottingham, Nottingham, United Kingdom. Electronic address: damianbragg@gmail.com. Bradley C C Physics, University of Nottingham, Nottingham, United Kingdom. El-Sharkawy A A Department of Gastrointestinal Surgery, University of Nottingham, Nottingham, United Kingdom. Chowdhury A A Department

Full Text available with Trip Pro

2017 Clinical nutrition (Edinburgh, Scotland) Controlled trial quality: uncertain

149. Adenovirus type 35-vectored tuberculosis vaccine has an acceptable safety and tolerability profile in healthy, BCG-vaccinated, QuantiFERON(®)-TB Gold (+) Kenyan adults without evidence of tuberculosis. (PubMed)

Adenovirus type 35-vectored tuberculosis vaccine has an acceptable safety and tolerability profile in healthy, BCG-vaccinated, QuantiFERON(®)-TB Gold (+) Kenyan adults without evidence of tuberculosis. In a Phase 1 trial, we evaluated the safety of AERAS-402, an adenovirus 35-vectored TB vaccine candidate expressing 3 Mycobacterium tuberculosis (Mtb) immunodominant antigens, in subjects with and without latent Mtb infection. HIV-negative, BCG-vaccinated Kenyan adults without evidence (...) after the second vaccine dose, slightly more so in QFT-G(+) subjects. CD4+ and CD8+ responses to Mtb antigen TB10.4 were minimal. Increases in Adenovirus 35 neutralizing antibodies from screening to end of study, seen in 50% of AERAS-402 recipients, were mostly minimal. This small study confirms acceptable safety and tolerability profiles for AERAS-402, in line with other Phase 1 studies of AERAS-402, now to include QFT-G(+) subjects.Published by Elsevier Ltd.

Full Text available with Trip Pro

2017 Vaccine Controlled trial quality: uncertain

150. Red blood cell concentrates treated with the amustaline (S-303) pathogen reduction system and stored for 35 days retain post-transfusion viability: results of a two-centre study. (PubMed)

and Control RBCs was comparable (83·2 ± 5·2 and 84·9 ± 5·9%, respectively; P = 0·06) and consistent with the US Food and Drug Administration (FDA) criteria for acceptable RBC viability. There were differences in the T50 between Test and Control RBCs (33·5 and 39·7 days, respectively; P < 0·001), however, these were within published reference ranges of 28-35 days. The AUC (per cent surviving × days) for Test and Control RBCs was similar (22·6 and 23·1 per cent surviving cells × days, respectively; P > 0·05 (...) Red blood cell concentrates treated with the amustaline (S-303) pathogen reduction system and stored for 35 days retain post-transfusion viability: results of a two-centre study. Pathogen reduction technology using amustaline (S-303) was developed to reduce the risk of transfusion-transmitted infection and adverse effects of residual leucocytes. In this study, the viability of red blood cells (RBCs) prepared with a second-generation process and stored for 35 days was evaluated in two different

Full Text available with Trip Pro

2017 Vox sanguinis Controlled trial quality: uncertain

151. Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age. (PubMed)

Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age. Children 6 through 35 months of age are recommended to receive half the dose of influenza vaccine compared with older children and adults.This was a 6-site, randomized 2:1, double-blind study comparing full-dose (0.5 mL) trivalent inactivated influenza vaccine (TIV) with half-dose (0.25 mL) TIV in children 6 through 35 months (...) of age. Children previously immunized with influenza vaccine (primed cohort) received 1 dose, and those with no previous influenza immunizations (naive cohort) received 2 doses of TIV. Local and systemic adverse events were recorded. Sera were collected before immunization and 1 month after last dose of TIV. Hemagglutination inhibition antibody testing was performed.Of the 243 subjects enrolled (32 primed, 211 naive), data for 232 were available for complete analysis. No significant differences

Full Text available with Trip Pro

2017 Journal of the Pediatric Infectious Diseases Society Controlled trial quality: uncertain

152. Evaluating the Efficacy of Xylitol Wipes on Cariogenic Bacteria in 19- to 35-month-old Children: A Double-blind Randomized Controlled Trial (PubMed)

: Kayalvizhi G, Nivedha D, Sajeev R, Prathima GS, Suganya M, Ramesh V. Evaluating the Efficacy of Xylitol Wipes on Cariogenic Bacteria in 19- to 35-month-old Children: A Double-blind Randomized Controlled Trial. Int J Clin Pediatr Dent 2018;11(1):13-17. (...) Evaluating the Efficacy of Xylitol Wipes on Cariogenic Bacteria in 19- to 35-month-old Children: A Double-blind Randomized Controlled Trial Dental caries is an infectious disease with Streptococcus mutans as the main cariogenic bacteria. Children with early S. mutans colonization have a higher risk of developing dental caries than those with later colonization. Therefore, prevention or delay of S. mutans colonization may be advantageous for the prevention of early childhood caries (ECC

Full Text available with Trip Pro

2017 International journal of clinical pediatric dentistry Controlled trial quality: uncertain

153. Safety and Immunogenicity of Adenovirus 35 TB Vaccine Candidate in Adults with Active or Previous TB: a Randomized Trial. (PubMed)

Safety and Immunogenicity of Adenovirus 35 TB Vaccine Candidate in Adults with Active or Previous TB: a Randomized Trial. Administration of tuberculosis (TB) vaccines in participants with previous or current pulmonary TB may have the potential for causing harmful postvaccination immunologic (Koch-type) reactions.To assess the safety and immunogenicity of three dose levels of the AERAS-402 live, replication-deficient adenovirus 35-vectored TB candidate vaccine, containing three mycobacterial (...) antigens, in individuals with current or previous pulmonary TB.We performed a phase II randomized, placebo-controlled, double-blinded dose-escalation study in an HIV-negative adult South African cohort (n = 72) with active pulmonary TB (on treatment for 1-4 mo) or pulmonary TB treated at least 12 months before study entry and considered cured. Safety endpoints included clinical assessment, flow volume curves, diffusing capacity of the lung for carbon monoxide, pulse oximetry, chest radiograph, and high

2017 American Journal of Respiratory and Critical Care Medicine Controlled trial quality: uncertain

154. Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib

Pooled MM-009 and MM-010 ooled MM-009 and MM-010 trials trials P Petrucci et al. (1989) etrucci et al. (1989) Study design Study design Multinational randomised controlled trial Single-arm trial P Patients in the atients in the trial trial About 35% of patients had 1 prior therapy and about 65% had had at least 2 prior therapies Patients had disease that had relapsed or was refractory to chemotherapy. The number of prior therapies was not reported. Sample size Sample size 353 351 34 Interv (...) Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib L Lenalidomide plus de enalidomide plus dexamethasone for xamethasone for multiple m multiple my yeloma after 1 treatment with eloma after 1 treatment with bortezomib bortezomib T echnology appraisal guidance Published: 26 June 2019 www.nice.org.uk/guidance/ta586 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

155. Findings Series 35 - 'Out of School' Foods

of the small area based three-city deprivation measure, has allowed identification of communities in Glasgow which, although almost identical to similar sized areas in Liverpool and Manchester in terms of their socio-economic characteristics, have significantly poorer health outcomes. These will now be the focus for a second, qualitative, phase of research. 2 35 Exploring the Nutritional Quality of ‘Out of School’ Foods Popular with School Pupils 6 Figure 1 FSM Entitlement in Pilot Secondary Schools Source (...) Findings Series 35 - 'Out of School' Foods BRIEFING PAPER September 2010 Investigating a ‘Glasgow Effect’: why do equally deprived UK cities experience different health outcomes? FINDINGS SERIES 25 June 2012 35 Exploring the Nutritional Quality of ‘Out of School’ Foods Popular with School PupilsBRIEFING PAPER FINDINGS SERIES 25 Investigating a ‘Glasgow Effect’: why do equally deprived UK cities experience different health outcomes? KEY FINDINGS % This report summarises a range of analyses

2012 Glasgow Centre for Population Health

156. β-asarone prevents Aβ25-35-induced inflammatory responses and autophagy in SH-SY5Y cells: down expression Beclin-1, LC3B and up expression Bcl-2 (PubMed)

β-asarone prevents Aβ25-35-induced inflammatory responses and autophagy in SH-SY5Y cells: down expression Beclin-1, LC3B and up expression Bcl-2 Alzheimer's disease (AD) is a chronic progressive neurodegenerative disorder. Inflammatory responses and autophagy have been implicated in the amyloid-β (Aβ) aggregation in Alzheimer's disease. Although major evidence indicates that macro autophagy is involved in the pathogenesis of AD, its exact role is still unclear. β-asarone, a major component (...) -asarone could significantly reduce Beclin-1, LC3B and increase anti-apoptotic protein Bcl-2 level. These results showed that β-asarone protected cells from Aβ25-35 induced inflammation and attenuated autophagy via Bcl-2/Beclin-1 pathway. Our findings suggested that β-asarone might be a potential preventive drug for AD.

Full Text available with Trip Pro

2015 International journal of clinical and experimental medicine

157. Interleukin-35 Inhibits Endothelial Cell Activation by Suppressing MAPK-AP-1 Pathway (PubMed)

Interleukin-35 Inhibits Endothelial Cell Activation by Suppressing MAPK-AP-1 Pathway Vascular response is an essential pathological mechanism underlying various inflammatory diseases. This study determines whether IL-35, a novel responsive anti-inflammatory cytokine, inhibits vascular response in acute inflammation. Using a mouse model of LPS-induced acute inflammation and plasma samples from sepsis patients, we found that IL-35 was induced in the plasma of mice after LPS injection as well (...) as in the plasma of sepsis patients. In addition, IL-35 decreased LPS-induced proinflammatory cytokines and chemokines in the plasma of mice. Furthermore, IL-35 inhibited leukocyte adhesion to the endothelium in the vessels of lung and cremaster muscle and decreased the numbers of inflammatory cells in bronchoalveolar lavage fluid. Mechanistically, IL-35 inhibited the LPS-induced up-regulation of endothelial cell (EC) adhesion molecule VCAM-1 through IL-35 receptors gp130 and IL-12Rβ2 via inhibition

Full Text available with Trip Pro

2015 The Journal of biological chemistry

158. HLA-DRα1-mMOG-35-55 treatment of experimental autoimmune encephalomyelitis reduces CNS inflammation, enhances M2 macrophage frequency, and promotes neuroprotection (PubMed)

HLA-DRα1-mMOG-35-55 treatment of experimental autoimmune encephalomyelitis reduces CNS inflammation, enhances M2 macrophage frequency, and promotes neuroprotection DRα1-mouse(m)MOG-35-55, a novel construct developed in our laboratory as a simpler and potentially less immunogenic alternative to two-domain class II constructs, was shown previously to target the MIF/CD74 pathway and to reverse clinical and histological signs of experimental autoimmune encephalomyelitis (EAE) in DR*1501-Tg mice (...) in a manner similar to the parent DR2β1-containing construct.In order to determine whether DRα1-mMOG-35-55 could treat EAE in major histocompatibility complex (MHC)-mismatched mice and to evaluate the treatment effect on central nervous system (CNS) inflammation, C57BL/6 mice were treated with DRα1-mMOG-35-55. In addition, gene expression profile was analyzed in spinal cords of EAE DR*1501-Tg mice that were treated with DRα1-mMOG-35-55.We here demonstrate that DRα1-mMOG-35-55 could effectively treat EAE

Full Text available with Trip Pro

2015 Journal of neuroinflammation

159. Prediction of small-for-gestational-age neonates: screening by placental growth factor and soluble fms-like tyrosine kinase-1 at 35-37 weeks. (PubMed)

Prediction of small-for-gestational-age neonates: screening by placental growth factor and soluble fms-like tyrosine kinase-1 at 35-37 weeks. To investigate the potential value of maternal serum placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) at 35-37 weeks' gestation in the prediction of delivery of small-for-gestational-age (SGA) neonates, in the absence of pre-eclampsia (PE).This was a screening study in singleton pregnancies at 35-37 weeks, including 158 (...) group, the median PlGF multiples of the median (MoM) was significantly lower and the median sFlt-1 MoM was significantly higher in the SGA group. Combined screening by maternal factors and EFW at 35-37 weeks predicted, at 10% false-positive rate (FPR), 90%, 92% and 94% of SGA neonates with birth weight < 10(th), < 5(th) and < 3(rd) percentiles, respectively, delivering < 2 weeks following assessment; the respective values for SGA delivering ≥ 37 weeks were 66%, 73% and 80%. When PlGF and sFlt-1 were

Full Text available with Trip Pro

2015 Ultrasound in Obstetrics and Gynecology

160. Lung Function and CT Densitometry in Subjects with alpha-1-Antitrypsin Deficiency and Healthy Controls at 35 Years of Age. (PubMed)

Lung Function and CT Densitometry in Subjects with alpha-1-Antitrypsin Deficiency and Healthy Controls at 35 Years of Age. Alpha-1-antitrypsin (AAT) deficiency is a genetic risk factor for pulmonary emphysema. In 1972-74 all 200,000 Swedish new-born infants were screened for AAT deficiency. The aim of the present study was to investigate whether the PiZZ and PiSZ individuals identified by this screening have signs of emphysema and the role of smoking in this, compared with a random sample (...) of control subjects at 35 years of age. The study participants underwent complete pulmonary function tests (PFT) and CT densitometry. The fifteenth percentile density (PD15) and the relative area below -910 HU (RA-910) were analyzed. Fifty-four PiZZ, 21 PiSZ and 66 PiMM control subjects participated in the study. No significant differences were found in lung function between the never-smoking AAT-deficient and control subjects. The 16 PiZZ ever-smokers had significantly lower carbon monoxide transfer

2015 COPD

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>